Want to see PCRX full AI Analyst Report?
Top Page
Pacira Pharmaceuticals
(NASDAQ:PCRX)
Select Model
Select Model
Rating:68Neutral
Price Target:
$27.00
▲(5.76% Upside)
Action:Reiterated
Date:10/09/26
The score is driven primarily by strong cash-flow generation and improving balance-sheet leverage, plus supportive deal-related upside from the announced all-cash acquisition. These positives are tempered by thin/volatile profitability, a technically neutral setup with slightly negative MACD, and a high P/E valuation with no dividend yield provided.
Positive Factors
Strong Cash Generation
Strong operating and free cash flow, alongside cash conversion that generally tracks reported earnings, indicates Pacira is generating substantial underlying liquidity. This supports research investment, commercial execution, and balance-sheet resilience while reducing reliance on external financing over the next several quarters.
Negative Factors
Volatile Profitability
The shift from profit to a sharp loss and back to only modest profitability shows that earnings quality remains inconsistent. Thin operating and net margins leave less protection against execution setbacks, making sustained revenue growth and cost discipline important for financial stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Cash Generation
Strong operating and free cash flow, alongside cash conversion that generally tracks reported earnings, indicates Pacira is generating substantial underlying liquidity. This supports research investment, commercial execution, and balance-sheet resilience while reducing reliance on external financing over the next several quarters.
Read all positive factors
Pacira Pharmaceuticals (PCRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.45B
Dividend YieldN/A
Average Volume (3M)1.90M
Price to Earnings (P/E)103.2
Beta (1Y)0.67
Revenue Growth5.71%
EPS GrowthN/A
CountryUS
Employees827
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.35
Shares Outstanding39,861,885
10 Day Avg. Volume4,609,544
30 Day Avg. Volume1,904,860
Financial Highlights & Ratios
PEG Ratio-1.51
Price to Book (P/B)1.66
Price to Sales (P/S)1.59
P/FCF Ratio8.44
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit2.00
Enterprise Value/Ebitda10.31
Forecast
1Y Price Target
$34.79Price Target Upside36.25% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)2.9
Revenue Forecast (FY)$754.33M
Pacira Pharmaceuticals Business Overview & Revenue Model
Company Description
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable ...
How the Company Makes Money
Pacira primarily makes money by selling its branded, prescription products to healthcare providers and institutions, generating revenue from product sales. The largest revenue driver is typically EXPAREL, which is purchased for use in hospitals an...
Pacira Pharmaceuticals Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call highlighted solid financial performance (6% revenue growth, robust adjusted EBITDA, strong cash position), meaningful commercial progress (major payer wins covering ~150M lives, EXPAREL and ZILRETTA momentum), important pipeline and manufacturing milestones (PCRX-201 manufacturing, multiple imminent readouts), and a strategic portfolio move (iovera divestiture with up to $140M consideration). Key challenges include softness in elective inpatient soft tissue procedures driven by macroeconomic factors, a decline in gross margin versus prior year, higher R&D and SG&A spend, and modest near-term moderation in EXPAREL volume growth. Overall, the positives — including clear payer wins, pipeline catalysts, cash generation, and strategic partnerships — outweigh the operational and margin headwinds.Positive Updates
Consolidated Revenue Growth
Second quarter total revenues of $192.4 million, up 6% year-over-year versus Q2 2025.
Negative Updates
Macroeconomic Headwinds Impacting Elective Procedures
Softness in elective soft tissue procedures, particularly in hospital inpatient settings where EXPAREL is not reimbursed outside the bundle, led to variable procedure demand and moderated near-term growth in some segments.
Read all updates
Q2-2026 Updates
Positive
Negative
Consolidated Revenue Growth
Second quarter total revenues of $192.4 million, up 6% year-over-year versus Q2 2025.
Read all positive updates
Company Guidance
Pacira updated 2026 guidance to total revenue of $735–760M (down from $745–770M reflecting the Zimmer/iovera divestiture) while reiterating EXPAREL net product sales of $600–620M; SG&A is now guided to $310–330M (vs. prior $320–340M), stock‑based compensation $54–59M (vs. $54–62M), non‑GAAP gross margin 77–79%, non‑GAAP R&D $105–115M, and depreciation of about $30M, with ~ $7M expected from a veterinary licensing agreement; Q2 datapoints cited were revenue $192.4M (+6% y/y), EXPAREL net sales $147.8M (+3%) with ~4% volume growth, Q2 non‑GAAP gross margin 78%, GAAP net income $4.7M ($0.12/sh), adjusted EBITDA ≈ $48.7M, and $251M cash/investments (plus a $70M upfront Zimmer payment); management noted near‑term margin benefit from selling lower‑cost EXPAREL inventory and expects Q4 margins to be slightly below the full‑year range due to higher‑cost inventory and shutdown-related costs.Pacira Pharmaceuticals Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
70
Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 746.16M | 726.41M | 700.97M | 674.98M | 666.82M | 541.53M |
| Gross Profit | 591.01M | 576.66M | 530.54M | 490.31M | 467.53M | 401.28M |
| EBITDA | 114.76M | 122.50M | 29.12M | 154.59M | 140.38M | 113.95M |
| Net Income | 14.64M | 7.03M | -99.56M | 41.95M | 15.91M | 41.98M |
Balance Sheet | ||||||
| Total Assets | 1.24B | 1.26B | 1.55B | 1.57B | 1.68B | 2.08B |
| Cash, Cash Equivalents and Short-Term Investments | 251.03M | 238.42M | 484.62M | 278.58M | 288.65M | 656.41M |
| Total Debt | 412.12M | 454.38M | 638.85M | 586.04M | 763.39M | 1.13B |
| Total Liabilities | 572.01M | 571.81M | 775.17M | 704.26M | 906.19M | 1.34B |
| Stockholders Equity | 671.98M | 693.11M | 778.35M | 870.13M | 775.01M | 730.41M |
Cash Flow | ||||||
| Free Cash Flow | 179.51M | 136.66M | 178.75M | 139.49M | 115.20M | 79.85M |
| Operating Cash Flow | 187.66M | 151.99M | 189.39M | 154.65M | 145.27M | 125.72M |
| Investing Cash Flow | 94.15M | 99.48M | -83.28M | 77.54M | -225.19M | -20.79M |
| Financing Cash Flow | -376.18M | -369.63M | 17.36M | -183.03M | -401.53M | 380.69M |
Pacira Pharmaceuticals Technical Analysis
Positive
25.53
Price Trends
27.53
Positive
26.13
Positive
24.46
Positive
Market Momentum
3.02
Negative
83.61
Negative
15.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCRX, the sentiment is Positive. The current price of 25.53 is below the 20-day moving average (MA) of 31.31, below the 50-day MA of 27.53, and above the 200-day MA of 24.46, indicating a bullish trend. The MACD of 3.02 indicates Negative momentum. The RSI at 83.61 is Negative, neither overbought nor oversold. The STOCH value of 15.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PCRX.
Pacira Pharmaceuticals Risk Analysis
Pacira Pharmaceuticals disclosed 73 risk factors in its most recent earnings report. Pacira Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pacira Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $1.45B | 103.18 | 2.13% | ― | 5.71% | ― | |
68 Neutral | $1.67B | 14.96 | 19.19% | ― | 30.90% | ― | |
68 Neutral | $1.11B | 15.06 | 10.11% | 3.43% | 1.02% | -38.09% | |
64 Neutral | $756.27M | 14.98 | 15.96% | ― | 14.31% | 34.35% | |
61 Neutral | $47.47B | 67.72 | 9.18% | 5.80% | 4.40% | ― | |
58 Neutral | $6.34B | 40.60 | -326.75% | ― | 9.28% | 4917.17% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PCRX
Pacira Pharmaceuticals
36.34
14.68
67.77%
TEVA
Teva
40.21
21.71
117.35%
ANIP
ANI Pharmaceuticals
73.75
-21.15
-22.29%
AMPH
Amphastar Pharmaceuticals
26.04
1.32
5.34%
COLL
Collegium Pharmaceutical
23.50
-12.04
-33.88%
AMRX
Amneal Pharmaceuticals
20.48
10.06
96.55%
Pacira Pharmaceuticals Corporate Events
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresM&A Transactions
Pacira to be acquired by Viatris in cash deal
Positive
Oct 8, 2026
Pacira BioSciences, Inc., a specialist in non-opioid pain therapies with flagship products EXPAREL and ZILRETTA and a growing musculoskeletal pain pipeline, generated about $746 million in revenue and $177 million in adjusted EBITDA in the twelve ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.